Clinical answers at semiconductor speed. Our BioFET platform delivers results in minutes — not days — across infectious disease, neurodegeneration, and oncology.
Novascope is a BioIC company — applying semiconductor engineering rigor to biomolecular detection. Every layer — chip, reader, cartridge, software, antibodies, surface chemistry — is designed, built, and owned by Novascope. Zero external silicon IP. Zero royalties. End-to-end.
3 chip series (NS01/NS02/NS03). UMC foundry. 2.4B sensors per biochip. 100% proprietary silicon IP — zero royalties.
Antifouling + high specificity. Flexible linker-probe pair. Core trade secret for manufacturing yield and femtogram sensitivity.
In-house buffer system, ZNA probes, VHH nanobodies & IgG mAbs. 10+ antibody families developed from animal to chip.
~200-component reader with in-house firmware. Disposable cartridge with microfluidics. Full software stack for hospital integration.
Proprietary signal-to-noise algorithms at femtogram sensitivity. Smart manufacturing QC. AI-implemented automation.
~100K bacterial isolates, 394 species. PET-validated AD samples. Certified contract lab for regulatory validation.
Complete diagnostic workflow in under 60 minutes
UMC CMOS fab
50K chips/lot
Surface chemistry links probes
Blood or plasma specimen
FET detects charge changes
Digital readout via reader
AI-powered clinical output
Six successful chip generations. Each manufactured at UMC. Each fully validated.
High-precision FET for surface-charge detection. Up to 8 targets simultaneously. 3×3 mm die, 2.4 billion sensor sites. All current pipeline products built on NS01C.
High-density array for scalable multiplexing across large biomarker panels. Suited for pathogen panels and AMR profiling.
Integrates FET + photodiode on single die — hybrid electrical-optical detection for expanded assay flexibility.
Unprecedented detection density: 2.4 billion sensors per biochip, 300M per sensing block (0.5 mm²), 4M per sensing unit (6 μm²).
Ready for clinical validations and pilot manufacturing
CMOS FET biosensor at UMC
Microfluidics-based handling
Single-use NovaCHIP cartridge
Compact POC reader
A complete IVD instrument designed in-house. ~200 components including touch panel, barcode scanner, motion control, and custom sensor PCB supporting 1–8 chips per run. Cross-platform verified against Quanterix SIMOA.
A walled garden: zero external IP dependencies, zero royalties
IP spans chip architecture, sensing circuitry, surface chemistry, reagent systems, and integrated platforms.
Chip design, circuit layout, mask design, foundry validation. Reader hardware, firmware, protocols, software. Antibodies, nanobodies, probes, surface chemistry. Cartridge, microfluidics, sample prep. AI signal processing — all developed internally with full patent ownership.
The cleanest IP table in the diagnostic semiconductor space.
| NanoDx | Paragraf | NOVASCOPE | |
|---|---|---|---|
| Founded | 2010 / US | 2017 / UK | 2022 / Taiwan |
| Device | Silicon nanowire FET | Monolayer graphene FET | Extended-gate FET (CMOS) |
| Challenge | Sensor reproducibility | Scalability, graphene uniformity | Clinical validation at scale |
| Production | In development | Pilot production | Pilot production |
| Cost/Test | Not yet available | $143 | COGS ~$10 |
| Capital Raised | $30M (Series C, 2020) | $85M (Series C, 2025) | $22.5M (Series A+B) |
Competitor data from publicly available sources, Q1 2026.
Validated through IRB-approved protocols at Chang Gung Memorial Hospital, one of Asia's largest medical centers.
88 clinical samples at a single center. LOD of 10² cfu/mL from non-cultured whole blood — pathogen ID in under 60 min vs. 2–7 days for blood culture.
Neurofilament light chain (NfL) is a pan-neurodegeneration biomarker elevated in AD, MS, ALS, TBI, and Parkinson's.
Correlation vs. Quanterix SIMOA (gold standard)
pTau 217/231 assays in development for AD-specific diagnosis. In-house antibody production provides competitive moat.
Validated under IRB-approved protocol at Chang Gung Memorial Hospital.
LOD of 10² cfu/mL from non-cultured whole blood (n=88, CGMH). Orders of magnitude improvement over culture-dependent methods.
In-house antibodies validated with immunohistochemistry on human brain tissue from AD patients
Real clinical specimens powering probe design and validation
A single semiconductor platform addressing multiple high-value clinical applications.
Sepsis costs $24B annually in US hospitals, with survival dropping 7.6% per hour of delayed treatment. Our platform delivers results from uncultured whole blood in under one hour.
| Platform | Specimen | Time | Sensitivity | Price/Test |
|---|---|---|---|---|
| NOVASCOPE | Whole blood | <1 hr | 97% | <$100 |
| BioFire BCID2 | Cultured | >1 day | >90% | $150–180 |
| T2 Bacteria | Whole blood | <5 hrs | 91–96% | $300–450 |
| Roche Eplex | Cultured | <15 hrs | >90% | $180–220 |
With FDA approval of anti-amyloid therapies, blood-based biomarker testing is essential. Current tests require $200K+ instruments. Our platform delivers results in minutes at the point of care.
| Platform | Stage | Turnaround | Machine Cost | Price/Test |
|---|---|---|---|---|
| NOVASCOPE | Under dev. | Minutes | <$50K | ~$200 |
| Fujirebio | FDA cleared | Hours–days | ~$200K | ~$600 |
| Roche | FDA cleared | Hours–days | ~$200K | ~$600 |
| Quanterix | LDT service | Days/batch | $300–400K | ~$500 |
Nucleic acid-based detection of EGFR, ALK, ROS1, BRAF, NTRK, RET, K-RAS, METex14. ctDNA detection via FET platform.
POC diagnostics for livestock health. Probes for PRRSV, PEDV, PCV1-4, CSFV, PRV, and SB.
Three converging forces create an unprecedented window for semiconductor-powered diagnostics.
1.27M deaths annually from AMR. Sepsis costs $24B in US hospitals. Every 60 min of delay increases mortality 7.6%. Blood culture is fundamentally too slow.
FDA approval of lecanemab and donanemab creates massive demand for blood-based biomarker screening. Current tests need $200K+ instruments. Market needs affordable, fast, decentralized testing.
Taiwan's ecosystem provides unmatched precision and cost. As the first bio-fabless company at UMC, COGS ~$10/test vs. $143+ for competitors. Same cost curve that transformed computing.
Multiple revenue streams from a single semiconductor platform.
Razor/blade model — instrument placement + recurring cartridge sales. Target: instrument <$50K, test ~$100–200. 5K units/month pilot → 50K/month at scale.
Antibody and ELISA kit sales. Near-term revenue from proprietary antibodies. 77 clones developed, 27 completed, 6 commercially available.
White-label biochip platform for strategic partners. Active discussions with Delta, Illumina, TauRx, Blot.
Contract lab services leveraging ~100K clinical isolate biobank. Revenue from validation testing and regulatory studies.
Company incorporated in Hsinchu and San Diego
ISO 13485 clean room lab established
98% accuracy sepsis • R²=0.97 NfL • 77 antibody clones • FDA Class I • Pilot production 5K/month
40+ patents filed • Multi-center trial prep
TFDA & FDA submissions • Commercial launch prep
Revenue inflection from diagnostic products
Deep expertise spanning IC design, clinical medicine, regulatory affairs, and capital markets.
20+ years IC & biotech. Former VP, Richtek Technology (MediaTek).
Stanford Top 2% scientist. AI & clinical research at Chang Gung.
Former FDA Division Director. UCSD Bioengineering. 20+ years regulatory.
18+ years ASIC design. Chip architecture lead for NS01/02/03.
Surface chemistry & antibody engineering. Leads NovaBIO & NovaLINK.
25 years deep-tech equity research. Taipei & London markets.
Novascope sits at the intersection of semiconductors and diagnostics — with a defensible platform and clear path to commercialization.
TFDA-first strategy accelerates FDA/CE pathway.
Partnerships with CGMH, NTUH, VGH. OEM with Delta, Illumina, TauRx. China: Shanghai Chang Hai.
Only standard CMOS FET platform. COGS $10/test vs. $143+. Complete E2E ownership — no royalties.
UMC foundry ensures semiconductor-grade manufacturing repeatability at volume.
Raised: $9M (2025) | Total capital raised to date: $22.5M
Multi-site validation, regulatory submissions
Pilot-to-production scale-up
San Diego lab, FDA filings
Distribution partnerships, market access